SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Crudes rise amid Iran-related tensions and reported threats to shipping and energy infrastructure around the Strait of Hormuz is driving attention to USO, with traders focused on possible supply disruptions and depleted oil reserves. The community is split between bulls betting on further gains if conflict escalates and bears expecting a sharp pullback if diplomacy produces a deal; uncertainty around negotiations is adding volatility.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy CEO Jason Fews Bloomberg interview is drawing criticism for offering no quantitative update on the manufacturing ramp and signaling a delay to the Texas agreement, intensifying concerns about missed timelines and management transparency. Some traders remain bullish on the data-center power opportunity, but debate centers on whether the company can turn that demand into firm contracts and production growth.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp semiconductor selloff is being linked to Intels weak outlook and broader doubts about whether massive AI spending will generate adequate returns, alongside concerns about financing and forced selling. Traders are split between calling the decline an overdone, AI-demand-insensitive pullback and warning that the AI trade is unwinding further.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Discussion centers on Corvuss recent soquelitinib atopic dermatitis data and investor presentation: bullish traders call the early results encouraging, while skeptics question the small cohort, safety evidence, and lack of longer follow-up. Many also blame the sharp negative reaction on management setting expectations too high without announcing a partnership or other concrete development.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

XLP is drawing attention amid a rotation toward defensive consumer-staples stocks as technology weakens, with traders also highlighting a rebound from technical support and a push back toward recent highs. The tone is broadly bullish, though some caution that momentum is contracting and the sectors sharp run may be stretched.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on ImmunityBios upcoming Q3 results and expected November topline data from the Phase 3 QUILT-2.005 trial of ANKTIVA plus BCG in BCG-naive bladder cancer; the company has said the trial database is locked and an sBLA submission is planned for Q4. Bulls see the results and commercial growth as potential catalysts, while more cautious traders point to recent share-price weakness, competition, and uncertainty around execution; claims of short-driven suppression or a squeeze remain speculation.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas S&P 500 inclusion and strong earnings have drawn attention, alongside expectations that AI-agent adoption will increase demand for identity security. Traders see potential index-fund buying but debate whether the sharp run-up leaves the stock vulnerable to profit-taking, citing valuation concerns.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,251,444,473.510925 in circulation. The last known price of Stellar is 0.16965209 USD and is down -0.50 over the last 24 hours. It is currently trading on 848 active market(s) with $69,462,156.70 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

Persistent selling and difficulty holding rebounds dominate discussion, with many traders blaming broader crypto weakness and expressing frustration over XLMs lagging price. Bulls point to Stellars institutional tokenization developments, including DTCC-related plans, while skeptics argue that adoption may not translate into token demand without stronger tokenomics.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,397.34014094 USD and is up 0.28 over the last 24 hours. It is currently trading on 12773 active market(s) with $12,152,377,915.37 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoin discussion is centered on the major Binance hack and the exchanges paused, phased resumption of withdrawals, with claims that most affected assets have been replenished easing some concern. Traders remain divided: bulls point to Bitcoin holding up and see a buying opportunity, while bears warn that shaken exchange trust and potential withdrawals could add selling pressure.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows collide with speculation about winter weather and storage: many traders cite mild or El Nio-influenced forecasts, ample supply, and bearish storage builds, while bulls look for a cold snap or seasonal rebound. The debate also centers on BOILs daily leverage, futures rolls, and decay, which traders warn can amplify losses even if natural-gas prices recover.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...

Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC

Anebulo Pharmaceuticals Announces Final Results of Tender Offer

Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer

How Is The Market Feeling About Anebulo Pharmaceuticals Inc?

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading 0.8% Higher - Still a Buy?

Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Up 0.8% - Here's Why...

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.

Anebulo Pharmaceuticals Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANEB Anebulo Pharmaceuticals Inc

Fundamentals

Latest ANEB News